AbbVie
AbbVie is a global biopharmaceutical company recognized for its commitment to workplace excellence, diversity, and innovation, with a focus on areas such as immunology, oncology, and neuroscience.
Sector
AbbVie operates in the biotechnology and pharmaceutical sector. The company focuses on core therapeutic areas, including immunology, oncology, neuroscience, eye care, and aesthetics. AbbVie’s products treat over 75 conditions across all stages of life and are available in over 175 countries.
Research and Development
Since its launch in 2013, AbbVie has invested more than $63 billion in research and development. In 2023, the company allocated $7.8 billion to R&D activities. AbbVie has a diverse pipeline with approximately 75 programs in mid- and late-stage development and around 60 programs in early-stage development. The company operates R&D sites in 17 countries, employing over 12,500 scientists and staff. The current pipeline includes over 90 compounds, devices, or indications.
Global Workforce and Partnerships
AbbVie employs approximately 50,000 people in over 70 countries. The company has 250+ active external innovation partners and operates 530+ patient support programs globally. AbbVie’s collaborative approach extends to its fundraising activities, with employees raising $21.7 million in 2022 for 12,600 nonprofits worldwide.
Awards and Recognition
AbbVie has been recognized on more than 40 workplace and diversity & inclusion lists. The company has been named on the DiversityInc 'Top 50 Companies for Diversity' list and has been included in the Dow Jones Sustainability World Index and North America Index. AbbVie is also listed in the FORTUNE 500 and has been recognized by FORTUNE as one of the '100 Best Companies to Work For.' Additionally, AbbVie has been included in the Great Place to Work 'World’s Best Workplaces,' the Human Rights Campaign Corporate Equality Index, and Science Magazine’s Top Employers list, among others.
Products
AbbVie’s products cover a broad spectrum of therapeutic areas, serving patients in over 175 countries. These products address over 75 different conditions, ranging from chronic diseases to specialized medical needs. AbbVie’s portfolio includes medicines in key areas such as immunology, oncology, neuroscience, eye care, and aesthetics.